Literature DB >> 8326127

Candidate vaccine antigens that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni.

D Richter1, S R Reynolds, D A Harn.   

Abstract

Vaccination with radiation-attenuated cercariae confers the highest levels of resistance to challenge infection in experimental schistosomiasis and requires Ag-specific T cells. Therefore, this study aimed to identify specific Ag that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni. Four experimental groups representing different levels of resistance in the vaccine model (C57BL/6J versus CBA/J mice vaccinated with 15- or 50-krad irradiated cercariae) were compared for in vitro lymphocyte proliferation and lymphokine production. Adult worm extracts fractionated by isoelectric focusing were used as Ag. Lymphocyte proliferation of all groups was limited to three consecutive isoelectric fractions (pH 4.6-6.3). Interestingly, the antibody response of these mice was directed to Ag in the same isoelectric fractions, three of which had previously been identified as paramyosin, heat shock protein 70, and the integral membrane protein Sm23. These Ag as well as two 28 kDa proteins, triosephosphate isomerase and glutathione S-transferase, in purified native or recombinant form or as a synthetic peptide, stimulated lymphocyte proliferation. Lymphocytes of vaccinated C57BL/6J mice generally showed higher levels of proliferation than did CBA/J mice. Interestingly, cells of once-vaccinated mice responded better than did cells of mice vaccinated three times. Lymphokine assays demonstrated that IL-2 and IL-4 was generally reduced after multiple vaccinations and varied qualitatively as well as quantitatively between mouse strains. This study substantiates that the five Ag, paramyosin, heat shock protein 70, triosephosphate isomerase, glutathione S-transferase, and the integral membrane protein Sm23, are important candidates for a defined antischistosomal vaccine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326127

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis.

Authors:  H Kakeya; H Udono; S Maesaki; E Sasaki; S Kawamura; M A Hossain; Y Yamamoto; T Sawai; M Fukuda; K Mitsutake; Y Miyazaki; K Tomono; T Tashiro; E Nakayama; S Kohno
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Characterization and protective potential of the immune response to Taenia solium paramyosin in a murine model of cysticercosis.

Authors:  J Vázquez-Talavera; C F Solís; L I Terrazas; J P Laclette
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 3.  Schistosomiasis-from immunopathology to vaccines.

Authors:  Donald P McManus; Robert Bergquist; Pengfei Cai; Shiwanthi Ranasinghe; Biniam Mathewos Tebeje; Hong You
Journal:  Semin Immunopathol       Date:  2020-02-19       Impact factor: 9.623

4.  Monitoring specific antibody responses against the hydrophilic domain of the 23 kDa membrane protein of Schistosoma japonicum for early detection of infection in sentinel mice.

Authors:  Jie Wang; Chuan-Xin Yu; Xu-Ren Yin; Wei Zhang; Chun-Yan Qian; Li-Jun Song; Xue-Dan Ke; Yong-Liang Xu; Wei He; Guo-Qun Cao
Journal:  Parasit Vectors       Date:  2011-09-10       Impact factor: 3.876

5.  Protective and anti-pathology effects of Sm fructose-1,6-bisphosphate aldolase-based DNA vaccine against schistosoma mansoni by changing route of injection.

Authors:  Mohamed Saber; Tarek Diab; Olft Hammam; Amr Karim; Amina Medhat; Mamdouh Khela; Ehab El-Dabaa
Journal:  Korean J Parasitol       Date:  2013-04-25       Impact factor: 1.341

Review 6.  Why the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A review.

Authors:  Rashika El Ridi; Hatem Tallima
Journal:  J Adv Res       Date:  2014-10-20       Impact factor: 10.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.